Semaglutide — the complete guide to weight loss and treatment
01 Mar
Semaglutide has changed the landscape of medical weight loss in a way that few substances have done before. From the Ozempic pen that revolutionized diabetes treatment to Wegovy that became the world’s most talked about weight loss drug — behind all these product names is the same molecule. We go through how semaglutide works in depth, which preparations are available in Sweden, what the research shows about weight loss and long-term effects, and how to navigate the different options.
Semaglutide — the substance behind several drugs
Semaglutide is a synthetic GLP-1 receptor agonist developed by the Danish pharmaceutical company Novo Nordisk. The molecule is designed to mimic the body’s own GLP-1 hormone but with a crucial modification: a fatty acid chain that binds to albumin in the blood and prevents the rapid breakdown to which the natural hormone is subjected. The result is a half-life of about seven days, compared to the GLP-1 hormone’s natural half-life of just a few minutes.
This prolonged action means that a single injection per week is sufficient to maintain a constant pharmacological effect. Semaglutide is sold under three brand names with different indications and dosages:
Ozempic is approved for type 2 diabetes in doses of 0.5 mg, 1 mg and 2 mg per week. It was the first semaglutide preparation on the market and has the broadest clinical experience base. Weight loss occurs as a secondary effect and has made Ozempic known far beyond the diabetes world.
Wegovy contains the same semaglutide but at the higher dose of 2.4 mg per week, approved specifically for chronic weight control in adults with BMI ≥30 or BMI ≥27 with weight-related complications. The difference to Ozempic is therefore primarily the dose level and the formal indication.
Rybelsus is semaglutide in tablet form — the world’s first oral GLP-1 drug. The maximum dose is 14 mg per day, but due to the low bioavailability (about 1%), the tablet gives a weaker effect than the injections. Rybelsus is approved for type 2 diabetes and offers a needle-free option for those who cannot tolerate injections.
How semaglutide causes weight loss
Semaglutide’s weight loss effect is not a single mechanism but an interplay of several parallel processes that together create a powerful appetite suppressant system.
The central effect takes place in the brain. Semaglutide crosses the blood-brain barrier and activates GLP-1 receptors in the hypothalamus and brainstem — the areas that regulate hunger and satiety. It is this central effect that causes patients to describe a fundamentally changed relationship with food: the hunger panic that normally occurs between meals is alleviated, cravings are reduced and portion sizes are reduced naturally without requiring willpower.
In the gastrointestinal tract, semaglutide slows gastric emptying, which means that food stays longer in the stomach and provides a prolonged feeling of satiety after a meal. This effect also contributes to the most common side effects—nausea and motion sickness—that most people experience during the ramp-up phase.
Insulin response is improved: semaglutide stimulates glucose-dependent insulin release, which means that insulin increases when blood sugar is high but not at normal levels. It reduces the risk of hypoglycemia compared to older diabetes drugs and stabilizes blood sugar throughout the day — something that indirectly reduces the blood sugar swings that drive sugar cravings and snacking.
Semaglutide weight loss — clinical trial results
The clinical evidence for semaglutide’s weight loss effect is extensive and comes mainly from two large study programs: SUSTAIN (Ozempic, diabetes) and STEP (Wegovy, weight loss).
STEP 1, the most cited study, included obese adults without diabetes. On the 2.4 mg weekly dose (Wegovy), participants lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% in the placebo group. Nearly one-third of participants achieved weight loss of 20% or more—figures previously only possible with bariatric surgery.
STEP 2 studied patients with type 2 diabetes and showed a mean weight loss of 9.6% with semaglutide 2.4 mg. The result is lower than in non-diabetics, which is consistent with diabetes making weight loss more difficult through metabolic adaptations.
The SUSTAIN studies with Ozempic (doses up to 1 mg) showed weight loss in the range of 4-6 kg over placebo, corresponding to 4-6% of body weight. It confirms that dose matters — the higher Wegovy dose gives significantly better results.
The SELECT study, published in 2023, also showed that semaglutide reduced the risk of major cardiovascular events (myocardial infarction, stroke, cardiovascular death) by 20% in obese patients without diabetes. It was the first time a weight-loss drug showed cardiovascular benefit in a randomized trial — a paradigm shift that is changing the way we look at treating obesity.
Semaglutide buy — alternative in Sweden
Buying semaglutide in Sweden requires a valid doctor’s prescription in all prescription forms. The ways to get there vary depending on your situation and which product you are looking for.
Via the health center or diabetes specialist, you get the most established route to Ozempic for type 2 diabetes. The subsidy makes the treatment affordable — with the high-cost protection, you pay a maximum of SEK 2,600 per year for all your prescription drugs.
Digital healthcare services have in recent years opened up the possibility of having Wegovy and Ozempic prescribed for weight loss after an online consultation. The process usually includes a health declaration, BMI assessment and sometimes blood tests. The cost varies but typically ends up at SEK 300–600 for the consultation, in addition to the drug price.
Obesity clinics and specialist clinics offer the most qualified assessment and can combine medical treatment with lifestyle interventions, psychological support and follow-up. It is the recommended route for patients with pronounced obesity (BMI ≥35) or weight-related complications.
As a research peptide, semaglutide is available through specialist suppliers. Research semaglutide is supplied as a freeze-dried powder that requires reconstitution with bacteriostatic water, correct dosing and refrigerated storage. It is an option for experienced users who understand the preparation process, but it places high demands on knowledge of handling and safety. An overview of available alternatives and comparisons can help you find the right product.
Long-term effects — what happens when you quit?
The STEP 4 study specifically looked at what happens after treatment ends. The results were unequivocal: participants who discontinued semaglutide after 20 weeks of treatment regained about two-thirds of their lost weight over the following year. Those who continued treatment maintained their weight loss and lost further.
This reveals a central truth about GLP-1-based therapy: semaglutide does not cure obesity — it controls it. Just as blood pressure medications control hypertension without eliminating the underlying cause, semaglutide treatment requires continuity to maintain efficacy. It’s not a regimen you do for six months and then stop — it’s a long-term treatment strategy.
However, there are strategies to minimize weight regain in the event of termination. Strength training during treatment preserves muscle mass, which maintains a higher basal metabolism. Establish sustainable eating habits while semaglutide suppresses appetite — it’s easier to build good habits when hunger isn’t driving the behavior. Taper the dose gradually rather than stopping suddenly, and discuss a possible switch to a lower maintenance dose with your prescriber.
Semaglutide versus tirzepatide
The closest competitor to semaglutide is tirzepatide (Mounjaro), which activates both GLP-1 and GIP receptors. In the SURMOUNT trials, tirzepatide showed an average weight loss of 20-22%—significantly more than semaglutide’s 15%. The head-to-head SURPASS-2 study confirmed that tirzepatide provided better blood sugar control and weight loss than semaglutide at the same treatment period.
However, semaglutide has advantages: a longer safety track with several years of clinical experience, cardiovascular evidence from the SELECT study, more available forms of preparation (injection and tablet) and wider availability in Swedish pharmacies. For patients who prioritize proven safety data over maximum weight loss, semaglutide may still be the first choice. A review of injectable weight loss drugs provides a broader perspective on the options available.
.entry-content